Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Carbidopa
Drug ID BADD_D00359
Description Carbidopa presents a chemical denomination of N-amino-alpha-methyl-3-hydroxy-L-tyrosine monohydrate. It potently inhibits aromatic amino acid decarboxylase (DDC) and due to its chemical properties, it does not cross the blood-brain barrier. Due to its activity, carbidopa is always administered concomitantly with [levodopa]. An individual formulation containing solely carbidopa was generated to treat nausea in patients where the combination therapy [levodopa]/carbidopa is not efficient reducing nausea.[T394] The first approved product by the FDA containing only carbidopa was developed by Amerigens Pharmaceuticals Ltd and approved on 2014.[L5110] On the other hand, the combination treatment of carbidopa/levodopa was originally developed by Watson Labs but the historical information by the FDA brings back to the approval of this combination therapy developed by Mayne Pharma in 1992.[L5113]
Indications and Usage Carbidopa is indicated with [levodopa] for the treatment of symptoms of idiopathic Parkinson disease, postencephalitic parkinsonism and symptomatic parkinsonism followed by carbon monoxide or manganese intoxication.[FDA label] The combination therapy is administered for the reduction of [levodopa]-driven nausea and vomiting.[FDA label] The product of carbidopa should be used in patients where the combination therapy of carbidopa/[levodopa] provide less than the adequate daily dosage.[FDA label] As well carbidopa can be used in patients where the dosages of carbidopa and [levodopa] require individual titration.[FDA label]
Marketing Status approved
ATC Code Not Available
DrugBank ID DB00190
KEGG ID D00558
MeSH ID D002230
PubChem ID 34359
TTD Drug ID D0P7JZ
NDC Product Code 62331-014; 67628-2001; 70710-1221; 12780-4420; 15894-0040; 49452-1692; 51504-0001; 51927-0251; 62991-2848; 43386-980; 58624-0621; 16714-067; 40032-980; 65977-0131; 59651-146; 63629-9193; 70771-1355; 38779-0202; 52423-0901; 70600-018; 63415-0024; 25010-711; 43975-220; 42799-123; 63629-1932
UNII MNX7R8C5VO
Synonyms Carbidopa | Methyldopahydrazine | MK-486 | MK 486 | MK486 | Lodosin | Lodosyn | MK-485 | MK 485 | MK485 | Carbidopa, (S)-Isomer | Carbidopa, (R)-Isomer
Chemical Information
Molecular Formula C10H14N2O4
CAS Registry Number 28860-95-9
SMILES CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haemoglobin decreased13.01.05.003---
Haemolytic anaemia01.06.03.002---
Hallucination19.10.04.003--
Headache17.14.01.001--
Heart rate irregular13.14.04.003---
Henoch-Schonlein purpura01.01.04.001; 10.02.02.004; 23.06.01.002; 24.07.06.003---
Hiccups07.01.06.009; 22.12.01.001--
Horner's syndrome06.09.04.002; 16.32.03.006; 17.05.01.004---
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypoaesthesia17.02.06.023; 23.03.03.081---
Hypotension24.06.03.002--
Insomnia17.15.03.002; 19.02.01.002--
Leukopenia01.02.02.001---
Libido increased19.08.03.002; 21.03.02.007--
Loss of consciousness17.02.04.004---
Malaise08.01.01.003--
Malignant melanoma16.03.01.001; 23.08.01.001---
Memory impairment17.03.02.003; 19.20.01.003--
Menopausal symptoms21.02.02.002---
Muscle spasms15.05.03.004--
Muscle twitching15.05.03.005---
Musculoskeletal pain15.03.04.007--
Mydriasis06.05.03.004; 17.02.11.003---
Myocardial infarction02.02.02.007; 24.04.04.009--
Nasopharyngitis11.01.13.002; 22.07.03.002---
Nausea07.01.07.001--
Nervousness19.06.02.003---
Neuroleptic malignant syndrome08.05.01.005; 12.03.01.003; 15.05.04.015; 17.05.02.003---
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages